skip to content

FDA grants Breakthrough Therapy Designation for Roche’s CD20xCD3 bispecific cancer immunotherapy mosunetuzumab recognising its potential in follicular lymphoma

Investors

Investor updates
view all

stay updated

get the latest news and updates to your inbox.